A clinical-stage biopharmaceutical company developing novel disease-modifying therapies for immunology and inflammatory diseases, with a focus on chronic fibrotic indications. The company's pipeline includes oral and inhaled small molecule inhibitors targeting ALK5/TGFβR1 for conditions like Crohn's disease and idiopathic pulmonary fibrosis, as well as HGF-mimetic monoclonal antibodies for antifibrotic and regenerative applications.